Microba Life Sciences Limited (MAP.AX)
Microba Life Sciences Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Brisbane, QLD, AU. The stock last traded at $0.05, up 0.00% on the session, giving a market capitalisation of $34.4M. Its beta of 2.09 implies it has historically moved more than the broad market.
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
Microba Life Sciences Limited is most often compared with the following Healthcare names: